HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US HBW Business News: OTC Migraine Treatment Device Cleared, Nestle Closes Aimmune Deal, More

Executive Summary

Cefaly touts first OTC dual-Purpose eTNS migraine device available in US; Nestle Health Science closes on its acquisition of Aimmune Therapeutics; Elderberry supplement marketer Matherson Organics complies with NAD recommendations rather than face FTC scrutiny; and nutrition product firm Vidafuel closes on $1.6m financing round.

You may also be interested in...

Nestle Pairs Nutrition Science Business With Pharma Firm Making Peanut Allergy Treatment

Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.

Elderberry Demand Loud But Matherson Organics Silent In NAD Review Of Immune Benefit Claim

The National Advertising Division says it will refer Matherson Organics to regulators for possible enforcement after it failed to provide a substantive response to an inquiry on an Instagram claim that suggested Vitamin Bounty Elderberry Immune Support could help prevent or treat COVID-19.

HBW Market News: COVID-19 Donations And Support, Shifts To Sanitizer Production

Boston coalition offers pro-bono legal help for small businesses, nonprofits; CBD firms Neptune Wellness Solutions and cbdMD respond to loosened US prohibitions for preparing sanitizers; Modere supplements provides first responders with free products; Young Living donates sanitizer in community; VidaFuel Nutition provides protein drinks to vulnerable kidney patients.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts